A venture fund backed by one of Detroit's largest health systems and Michigan's second-largest university has named the first two companies it is investing in, and in both cases the product is still being validated rather than used in routine patient care.
Henry Ford Health and Michigan State University Health Sciences announced on July 30 that the Henry Ford and MSU Innovation Fund has invested in LightHearted AI and M3D. The announcement did not disclose the size of either investment.
For patients in metro Detroit and mid-Michigan, this is not a story about a new option at their next appointment. It is a story about how technologies reach the exam room, and about a structural feature of the arrangement that is worth understanding: a health system is taking an equity position in companies whose products it may later evaluate, pilot, and purchase.
Two Companies, Neither Yet Cleared for Sale
LightHearted AI is developing a device called LightScope. According to the fund's announcement, it is a non-invasive technology that uses visible light to capture heart sound data and detect heart valve disease in under ten seconds. The company was co-founded by Lucrezia Cester and Dilip Rajeswari.
The regulatory status is stated plainly in the announcement and should not be skipped: the investment will support the company's continued clinical validation and commercialization work "as it prepares for regulatory approvals." That language indicates the device has not received FDA clearance and is not in general clinical use.
There is a discrepancy worth flagging. LightHearted AI's own website describes the technology as clinically validated and states that it delivers substantially higher signal-to-noise than a stethoscope. Those are company claims about a company product, and they sit alongside a partner announcement describing validation as ongoing. Readers should treat marketing language from any device company as a claim rather than a finding until independent data are published.
M3D is developing radiation imaging technology intended to let clinicians identify, locate, and visualize sources of radiation in real time. The stated purpose is improving radiation safety, treatment accuracy, and workflow. Co-founder and chief executive Mike Hopkins said the partnership brings clinical perspective alongside capital. The investment supports continued product development, clinical validation, and commercialization, which again indicates a pre-commercial stage.
Neither company's technology has been shown in published, independent clinical evidence to improve patient outcomes. That is normal for companies at this stage. It is also the reason an investment announcement is not a medical development.
Anatomy of a $10 Million Fund
The Innovation Fund is the venture arm of the Henry Ford and MSU Innovation Hub, announced in July 2025 as part of a 30-year partnership between the two institutions that also includes a new joint research center under construction in Detroit's New Center district.
Founding members committed $10 million, with Henry Ford Health contributing $5 million and Michigan State University and the MSU Research Foundation contributing $2.5 million each. The stated pace is roughly $2 million a year over about five years. Individual investments have been described as ranging from $100,000 to $250,000, targeting companies from pre-seed through Series A. The fund is managed by Red Cedar Ventures, the MSU Research Foundation's investment subsidiary.
Jeff Wesley, executive director of ventures at the MSU Research Foundation, manages the fund. Lisa Prasad, vice president and chief innovation officer at Henry Ford Health, sits on its board.
The fund's stated focus areas are precision medicine and diagnostics, digital health, artificial intelligence, medical devices, and remote monitoring. Companies must have a connection to Henry Ford Health, MSU, or the MSU Research Foundation at the time of investment or as a result of it.
"This is so much more than investing in startups," Henry Ford Health president and chief executive Bob Riney said when the hub launched.
When a Hospital Also Owns the Vendor
Health systems investing directly in the companies whose products they may adopt is now common practice, and it produces a set of incentives that deserve naming without being overstated.
The upside is real. A startup gets access to clinicians who can say whether a technology solves an actual problem, and to pilot sites where it can be tested in genuine workflow rather than in theory. Prasad framed the selection criteria in those terms, saying the fund looks for technologies "that have the potential to solve meaningful clinical problems." Many promising devices fail not because the engineering is wrong but because no one checked whether the workflow accommodated them.
The complication is structural. An institution holding equity in a device company has a financial interest in that company's success, and the same institution decides whether to pilot, adopt, and buy the product. There is no allegation of wrongdoing here, and disclosure practices at academic health systems have improved considerably. But patients enrolled in a pilot study of a device their hospital partly owns are entitled to know that, and the consent process is where that disclosure belongs.
This is also a question about who benefits. Fund-backed technologies get a validation pathway that competing products lack. Whether the resulting adoption decisions reflect comparative performance or investment position is not something an outside observer can assess from an announcement, and it is a reasonable thing for health systems to publish.
Reading Health System Investment News as a Patient
The practical guidance is short, because the practical implications for care right now are minimal.
Patients at Henry Ford Health facilities do not need to do anything differently. Neither technology is available as a standard test, and neither should be requested. Anyone invited to participate in a pilot study or clinical evaluation of a new device can ask whether the study sponsor has a financial relationship with the health system, what the device is meant to replace or add, and whether participation affects the standard care they would otherwise receive. Those questions are appropriate and routine.
Anyone concerned about heart valve disease should raise it with a clinician using the tools that exist today. Physical examination, echocardiography, and established imaging are the current standard, and none of that is changed by an early-stage investment.
Several things remain undisclosed. Investment amounts were not published. Neither company has announced an FDA submission date or a regulatory pathway. No peer-reviewed clinical performance data for either technology appear in the announcement. Whether either product will be piloted inside Henry Ford Health facilities, and on what terms, has not been stated. MedicalDaily will report FDA submissions or clearances if they are filed.
Frequently Asked Questions
What was announced? The Henry Ford and MSU Innovation Fund named its first two investments, in LightHearted AI and M3D, on July 30, 2026. Amounts were not disclosed.
What do the two companies do? LightHearted AI is developing LightScope, a device using visible light to capture heart sound data and detect valve disease. M3D is developing real-time radiation imaging technology.
Are either of these products FDA-cleared? No. The announcement describes both as in continued clinical validation, with LightHearted AI preparing for regulatory approvals. Neither is in general clinical use.
Who funds the venture fund? Henry Ford Health contributed $5 million and Michigan State University and the MSU Research Foundation contributed $2.5 million each, for an initial $10 million commitment announced in July 2025.
Can patients access these technologies now? No. Neither is available as a standard clinical test, and neither should be requested at an appointment.
Does a health system owning equity in a device maker matter? It creates an incentive structure worth understanding. Patients invited into a device pilot can ask whether the sponsor has a financial relationship with the health system.
What happens next? Both companies continue product development and validation. Regulatory submissions, clearances, and any published clinical performance data would be the next verifiable milestones.
